tafamidis has been researched along with Neoplasms* in 1 studies
1 other study(ies) available for tafamidis and Neoplasms
| Article | Year |
|---|---|
Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
CHI's 17th International Tri-Conference on Molecular Medicine, held in San Francisco, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on fragment-based drug discovery, quantum mechanical energy decomposition for the analysis of SARs, medicinal chemistry strategies and the role of imaging in drug discovery. Investigational drugs discussed include MLN-4924 (Millennium Pharmaceuticals Inc), GDC-0449 (Chugai Pharmaceutical Co Ltd/Curis Inc/F Hoffmann-La Roche Ltd/Genentech Inc/NCI), RDEA-119 (Ardea Biosciences Inc/Bayer HealthCare AG) and tafamidis (Fx-1006A; FoldRx Pharmaceuticals Inc). Topics: Alzheimer Disease; Amyloidosis; Anilides; Animals; Benzoxazoles; Chemistry, Pharmaceutical; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; HSP90 Heat-Shock Proteins; Humans; Macrocyclic Compounds; Neoplasms; Pharmacokinetics; Positron-Emission Tomography; Pyridines; Quantum Theory; Receptors, Immunologic; Receptors, Prostaglandin; Structure-Activity Relationship | 2010 |